Merck Patentgesellschaft

Patent Applications and Registrations

Patent applications and USPTO patent grants for Merck Patentgesellschaft.The latest application filed is for "polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride".

Company Profile

4.23.20

Merck Patentgesellschaft - Darmstadt DE
MERCK PATENTGESELLSCHAFT - MIT BESCHRANKTER HAFTUNG Darmstadt DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Polymorphic Forms Of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) Piperazine Hydrochloride App 20210251986 - Bathe; Andreas ; et al.	2021-08-19
Polymorphic Forms Of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) Piperazine Hydrochloride App 20190343831 - Bathe; Andreas ; et al.	2019-11-14
Polymorphic Forms Of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) Piperazine Hydrochloride App 20170182037 - Bathe; Andreas ; et al.	2017-06-29
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Grant 9,624,204 - Bathe , et al. April 18, 2	2017-04-18
Polymorphic Forms Of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) Piperazine Hydrochloride App 20150080411 - Bathe; Andreas ; et al.	2015-03-19
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride Grant 8,927,552 - Bathe , et al. January 6, 2	2015-01-06
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Grant 8,921,375 - Bathe , et al. December 30, 2	2014-12-30
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Grant 08921375 -	2014-12-30
Polymorphic Forms Of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) Piperazine Hydrochloride App 20140275115 - Bathe; Andreas ; et al.	2014-09-18
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Grant 8,673,921 - Bathe , et al. March 18, 2	2014-03-18
Polymorphic Forms Of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) Piperazine Hydrochloride App 20140024658 - Bathe; Andreas ; et al.	2014-01-23
Polymorphic Forms Of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine Hydrochloride App 20130102616 - Bathe; Andreas ; et al.	2013-04-25
Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride Grant 8,318,744 - Bathe , et al. November 27, 2	2012-11-27
Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride Grant 8,236,804 - Bathe , et al. August 7, 2	2012-08-07
Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride Grant 8,193,195 - Bathe , et al. June 5, 2	2012-06-05
Novel Use Of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine And Its Physiologically Acceptable Salts App 20120077825 - Bartoszyk; Gerd ; et al.	2012-03-29
Polymorphic Forms Of 1-'4-(5-cyanoindol-3-yl) Butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine Hydrochloride App 20110312971 - BATHE; Andreas ; et al.	2011-12-22
Polymorphic Forms Of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine Hydrochloride App 20110294825 - Bathe; Andreas ; et al.	2011-12-01
Polymorphic Forms Of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine Hydrochloride App 20110294824 - BATHE; Andreas ; et al.	2011-12-01
Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride Grant 7,981,894 - Bathe , et al. July 19, 2	2011-07-19
Combined etching and doping substances Grant 7,629,257 - Klein , et al. December 8, 2	2009-12-08
Use of substituted aminomethyl chromans Grant 7,618,988 - Bottcher , et al. November 17, 2	2009-11-17
Moulded bodies consisting of core-shell particles Grant 7,241,502 - Anselmann , et al. July 10, 2	2007-07-10
Method for producing compounds having a CF.sub.2O bridge Grant 7,105,708 - Kirsch , et al. September 12, 2	2006-09-12
Tricyclic quinoxaline and quinoline derivatives as a UV filter Grant 7,101,537 - Pfluecker , et al. September 5, 2	2006-09-05
Splice variant of head trauma induced cytoplasmatic calcium binding protein Grant 6,995,241 - Ducker , et al. February 7, 2	2006-02-07
Electro-optical liquid-crystal display Grant 6,800,338 - Jacob , et al. October 5, 2	2004-10-05
Tetracyclic and pentacyclic compounds, and their use in liquid-crystalline media App 20030078447 - Kirsch, Peer ; et al.	2003-04-24
Cyclic compounds useful in the treatment of dyslipidaemia, atherosclerosis and diabetes, pharamaceutical compositions and preparation process Grant 6,528,538 - Zeiller , et al. March 4, 2	2003-03-04
Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT1B/1D ligands Grant 6,509,340 - Van Amsterdam , et al. January 21, 2	2003-01-21
Process for the preparation of vinylene carbonate, and the use thereof Grant 6,395,908 - Seifert , et al. May 28, 2	2002-05-28
Laser-markable plastics Grant 6,376,577 - Kniess , et al. April 23, 2	2002-04-23
Silane compounds as additive in electrolytes for electrochemical cells App 20020012850 - Schmidt, Michael ; et al.	2002-01-31

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.